Skip to main content
. 2020 Jul 1;35(4):834–853. doi: 10.3904/kjim.2020.204

Figure 3.

Figure 3.

Suggestions for first-line treatment alternatives for patients with metastatic urothelial cancer. PD-L1, programmed death ligand 1; GP, gemcitabine plus cisplatin; MVAC, methotrexate, vinblastine, adriamycin, and cisplatin; ddMVAC, dose-dense MVAC; G-CSF, granulocyte colony-stimulating factor; GCb, gemcitabine plus carboplatin; BSC, best supportive care.